Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Dec 7, 2016
Last Price Change Open Day High 52-Week High
11.50
0.00    (0.000%) 0.00 N/A 27.11
Volume Previous Close Day Low 52-Week Low
N/A 11.50 N/A 9.40

View all »   RSSRecent Releases

Nov 28, 2016
Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications

Nov 9, 2016
Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference